President Names New NCAB Chair, Three New Members

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 7
Volume 9
Issue 7

WASHINGTON-President Clinton has named Phillip A. Sharp, PhD, of the Massachusetts Institute of Technology, to serve as chair of the National Cancer Advisory Board (NCAB). Dr. Sharp succeeds J. Michael Bishop, MD, of the University of California, San Francisco. The President has also named three new board members-James O. Armitage, MD, James Harold French, Jr., MD, and Arthur Wesley Nienhuis, MD. The 18-member board advises the President, the Secretary of Health and Human Services, and the director of the National Cancer Institute on the policies and activities of the NCI.

WASHINGTON—President Clinton has named Phillip A. Sharp, PhD, of the Massachusetts Institute of Technology, to serve as chair of the National Cancer Advisory Board (NCAB). Dr. Sharp succeeds J. Michael Bishop, MD, of the University of California, San Francisco. The President has also named three new board members—James O. Armitage, MD, James Harold French, Jr., MD, and Arthur Wesley Nienhuis, MD. The 18-member board advises the President, the Secretary of Health and Human Services, and the director of the National Cancer Institute on the policies and activities of the NCI.

Dr. Armitage is dean of the College of Medicine, University of Nebraska, Omaha. Dr. French is clinical assistant professor of plastic surgery, Georgetown University. Dr. Nienhuis, director, St. Jude Children’s Hospital, was reappointed to the board. He was first named a member in December 1998 to fill a vacant seat.

Related Videos
Immunotherapy may be an “elegant” method of managing colorectal cancer, says Gregory Charak, MD.
D. Ross Camidge, MD, PhD, spoke about how the approval of alectinib is the beginning of multiple other approvals for patients with ALK-positive NSCLC.
Nurses should be educated on cranial nerve impairment that may affect those with multiple myeloma who receive cilta-cel, says Leslie Bennett, MSN, RN.
Alexander Spira, MD, PhD, FACP, an expert on lung cancer
A panel of 4 experts on lung cancer
Treatment with cilta-cel may give patients with multiple myeloma “more time,” according to Ishmael Applewhite, BSN, RN-BC, OCN.
Nurses may need to help patients with multiple myeloma adjust to walking differently in the event of peripheral neuropathy following cilta-cel.
Rahul Gosain, MD; Nitin Jain, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Nitin Jain, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Nitin Jain, MD; and Rohit Gosain, MD, presenting slides